Your browser doesn't support javascript.
loading
Pain management for medical abortion before 14 weeks' gestation: A systematic review.
Reynolds-Wright, John J; Woldetsadik, Mulat A; Morroni, Chelsea; Cameron, Sharon T.
Afiliação
  • Reynolds-Wright JJ; MRC Centre for Reproductive Health, The Queen's Medical Research Institute, University of Edinburgh, 47 Little France Crescent, Edinburgh, EH16 4TJ, UK; Chalmers Centre for Sexual and Reproductive Health, NHS Lothian, 2a Chalmers Street, Edinburgh, EH3 9ES, UK. Electronic address: John.Reynolds-Wrig
  • Woldetsadik MA; Department of Obstetrics and Gynaecology, College of Medicine and Health Sciences, University of Gondar, PO Box 196, Gondar, Ethiopia.
  • Morroni C; MRC Centre for Reproductive Health, The Queen's Medical Research Institute, University of Edinburgh, 47 Little France Crescent, Edinburgh, EH16 4TJ, UK; Botswana Harvard AIDS Institute Partnership, Princess Marina Hospital, Plot No. 1836, Northring Road, Gaborone, Botswana.
  • Cameron ST; MRC Centre for Reproductive Health, The Queen's Medical Research Institute, University of Edinburgh, 47 Little France Crescent, Edinburgh, EH16 4TJ, UK; Chalmers Centre for Sexual and Reproductive Health, NHS Lothian, 2a Chalmers Street, Edinburgh, EH3 9ES, UK.
Contraception ; 116: 4-13, 2022 12.
Article em En | MEDLINE | ID: mdl-36055363
ABSTRACT

INTRODUCTION:

Abortion is common worldwide and increasingly abortions are performed at less than 14 weeks' gestation using medical methods, specifically using a combination of mifepristone and misoprostol. Medical abortion is known to be a painful process, but the optimal method of pain management is unclear. We sought to identify and compare pain management regimens for medical abortion before 14 weeks' gestation. STUDY

DESIGN:

We conducted our search in August 2019 and included randomized controlled trials (RCT) and observational studies of any pain relief intervention (pharmacological and non-pharmacological) for mifepristone-misoprostol combination medical abortion of pregnancies less than 14 weeks' gestation.

RESULTS:

We included four RCTs and one observational study. Due to the heterogeneity of study designs, interventions and outcome reporting, meta-analysis was not possible. Only one study found evidence of an effect between interventions on pain score a prophylactic dose of ibuprofen 1600mg likely reduces the pain score when compared to a dose of paracetamol 2000mg (MD 2.26/10 [CI 3-1.52 lower]). For other interventions (pregabalin 300mg vs placebo; ibuprofen 800mg vs placebo; therapeutic vs prophylactic administration of ibuprofen 800mg; ambulation vs non-ambulation during treatment) there appeared to be little to no difference with comparator.

CONCLUSIONS:

The findings of this review provide some support for the use of ibuprofen as a single dose given with misoprostol prophylactically, or in response to pain as needed. The optimal dosing of ibuprofen is unclear, but a single dose of ibuprofen 1600mg was shown to be effective and it was less certain whether 800mg was effective.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Misoprostol / Manejo da Dor Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Systematic_reviews Limite: Female / Humans / Pregnancy Idioma: En Revista: Contraception Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Misoprostol / Manejo da Dor Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Systematic_reviews Limite: Female / Humans / Pregnancy Idioma: En Revista: Contraception Ano de publicação: 2022 Tipo de documento: Article